Prevention of mother-to-child transmission of multi-drug resistant HIV-1 using maternal therapy with both enfuvirtide and tipranavir.

The management of multi-drug resistant HIV is a complex challenge in daily practice. Of particular concern is the presence of these strains in pregnant females as drug resistance does not only limit therapeutic options for the mother but may also reduce the effectiveness of perinatal prophylaxis. In order to avoid mother-to-child transmission clinicians may feel compelled to prescribe recently approved drugs for which there is none or only limited experience in pregnancy. We present a case of a pregnant female with drug-resistant HIV who received a mega-HAART regimen including the recently approved drugs enfuvirtide and tipranavir. Only limited information is available on perinatal prescription of enfuvirtide and the use of tipranavir in pregnancy has not yet been reported. (excerpt)